News

The U.S. Food and Drug Administration has issued the first emergency use authorization (EUA) for a COVID-19 antigen test, a new category of tests for use in the ongoing pandemic. These…
Read More...

Sorrento Therapeutics, Inc. and Mount Sinai Health System have agreed to join forces in the investigation and development of an antibody cocktail (COVI-SHIELD) to potentially treat…
Read More...

Recipharm has now secured supply of the active pharmaceutical ingredient (API) chloroquine phosphate for its drug Klorokinfosfat RPH Pharma and commenced manufacture of the product.…
Read More...

To accelerate national, multi-institutional efforts focused on mapping coronavirus transmission and epidemiological studies, Thermo Fisher Scientific announces the SARS-CoV-2…
Read More...

Schreiner MediPharm has developed a compact Booklet-Label for a needle protection system used in an international phase III clinical trial conducted by pharmaceutical corporation…
Read More...

Pfizer Inc. and BioNTech SE announced that the first participants have been dosed in the U.S. in the Phase 1/2 clinical trial for the BNT162 vaccine program to prevent COVID-19. The…
Read More...

Gilead Sciences, Inc. announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) has granted regulatory approval of Veklury (remdesivir) as a treatment for SARS-CoV-2…
Read More...

CluePoints, the premier provider of Risk-Based Quality Management (RBQM) and Data Quality Oversight Software for clinical trials, announced that its recently launched complimentary…
Read More...

ZYUS Life Sciences Inc., a company dedicated to improving quality of life through research and leadership in bio-pharmaceuticals and the development of innovative cannabinoid-based…
Read More...

Humanigen, Inc. a clinical stage biopharmaceutical company focused on preventing and treating cytokine storm with lenzilumab, the company’s proprietary Humaneered anti-human granulocyte…
Read More...

Lineage Cell Therapeutics, Inc. a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs, announced that Cancer Research UK’s Commercial…
Read More...

Enlivex Therapeutics Ltd. announced that an investigator-initiated multi-center Phase II clinical trial of AllocetraTM (formerly referred to as off-the-shelf AllocetraTM) in COVID-19…
Read More...

PTC Therapeutics, Inc. announced that it has entered into an agreement to acquire Censa Pharmaceuticals, Inc., a biopharmaceutical company focused on the development of CNSA-001…
Read More...

Laurent Pharmaceuticals Inc., a Montreal-based biopharmaceutical company, announced that it has obtained the approval from Health Canada to initiate RESOLUTION, a Phase 2 randomized…
Read More...

AVROBIO, Inc. and Magenta Therapeutics announced a research and clinical collaboration agreement to evaluate the potential utility of MGTA-117, Magenta’s novel targeted antibody-drug…
Read More...

AGC Biologics has been selected to commercially manufacture the treatment Clevegen for partner Faron Pharmaceuticals Oy, a clinical stage biopharmaceutical company. Clevegen is a…
Read More...

Bicycle Therapeutics plc, a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle) technology, announced…
Read More...

Alexion Pharmaceuticals, Inc. and Portola Pharmaceuticals, Inc. announced that they have entered into a definitive merger agreement for Alexion to acquire Portola, a commercial-stage…
Read More...

Today, the U.S. Food and Drug Administration approved Farxiga (dapagliflozin) oral tablets for adults with heart failure with reduced ejection fraction to reduce the risk of…
Read More...

Novartis announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the approval of Enerzair…
Read More...